NASDAQ: ELDNEledon Pharmaceuticals Inc Stock
$2.36-0.21 (-8.17%)
Updated Mar 24, 2023
ELDN Price
$2.36
Fair Value Price
$6.98
Market Cap
$32.47M
52 Week Low
$1.90
52 Week High
$4.15
P/E
-0.88x
P/B
0.23x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$38.39M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.06
Operating Cash Flow
-$28M
Beta
0.55
Next Earnings
Mar 30, 2023
Ex-Dividend
N/A
Next Dividend
N/A
ELDN Overview
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ELDN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ELDN ($2.36) is undervalued by 66.18% relative to our estimate of its Fair Value price of $6.98 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ELDN ($2.36) is significantly undervalued by 66.18% relative to our estimate of its Fair Value price of $6.98 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ELDN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ELDN due diligence checks available for Premium users.
Be the first to know about important ELDN news, forecast changes, insider trades & much more!
ELDN News
Valuation
ELDN fair value
Fair Value of ELDN stock based on Discounted Cash Flow (DCF)
Price
$2.36
Fair Value
$6.98
Undervalued by
66.18%
ELDN ($2.36) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ELDN ($2.36) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ELDN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ELDN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.88x
Industry
17.88x
Market
21.37x
ELDN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.23x
Industry
4.89x
ELDN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ELDN's financial health
Profit margin
Revenue
$0.0
Net Income
-$10.5M
Profit Margin
0%
ELDN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$149.6M
Liabilities
$8.5M
Debt to equity
0.06
ELDN's short-term assets ($67.57M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ELDN's short-term assets ($67.57M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ELDN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ELDN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.6M
Investing
$0.0
Financing
$0.0
ELDN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ELDN vs Biotech Stocks
Eledon Pharmaceuticals Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.